BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241001T170000
DTEND;TZID=Europe/Brussels:20241001T200000
DTSTAMP:20260726T101527
CREATED:20240517T115325Z
LAST-MODIFIED:20240517T115327Z
UID:7794-1727802000-1727812800@www.europabio.org
SUMMARY:Europe's Biotechnology & Biomanufacturing Future
DESCRIPTION:Biotechnology is a critical technology for global economic security\, health and sustainability. \n\n\n\nEurope’s world-leading research is translated into medicines\, food and next generation biomanufacturing across sectors in all European regions\, with employment\, skills and economic growth as part of a more sustainable\, healthy\, autonomous and competitive Europe. \n\n\n\nThe importance of biotechnology to Europe is now recognised through multiple actions. The European Commission Initiative “Boosting Biotechnology and Biomanufacturing in the EU” highlights the EU ambition to deliver biotechnology for competitiveness and societal impact alongside fast moving global regions\, whilst the Letta report highlights its significance within a well-functioning single market. It is amplified further through its specific inclusion in legislations such as STEP and the Net Zero Industry Act. \n\n\n\nEuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this reception to explore how biotechnology is used across sectors. Invited guests will meet the European innovators that deliver and use biotechnology and understand how it benefits the quality of life of all EU citizens. \n\n\n\nInnovative companies plus national and regional biotechnology associations will share their knowledge\, and guests will network across EU Institutions and other key stakeholders to discover how the European Union builds the future of biotechnology. \n\n\n\nFor more information\, contact: communications@europabio.org
URL:https://www.europabio.org/event/europes-biotechnology-biomanufacturing-future/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Event-Banner-for-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240930T140000
DTEND;TZID=Europe/Brussels:20240930T160000
DTSTAMP:20260726T101527
CREATED:20240719T161756Z
LAST-MODIFIED:20240927T055832Z
UID:8081-1727704800-1727712000@www.europabio.org
SUMMARY:How does a Novel Food get to your plate?
DESCRIPTION:This EuropaBio’s webinar will focus on the pathway to market for Novel Foods\, from initial development in R&D through to consumer uptake while going through risk assessment and approval. Each speaker will cover a key point along the value chain\, including illustrative examples and case studies where relevant.    \n\n\n\nThe event will be moderated by Hannah Lester\, CEO at Atova Consulting.  \n\n\n\nThe confirmed speakers are: \n\n\n\n\nMuriel Dewilde\, Business Development Manager\, Bio Base Europe Pilot Plant\n\n\n\nErmolaos Ververis\, Scientific Officer Nutrition & Food Innovation Unit\, EFSA\n\n\n\nTimen Van Haaster\, Public Affairs & Communications Director\, HollandBio\n\n\n\nAnders Nelving\, Line Solution Manager\, Tetra Pak\n\n\n\nPer Falholt\, CSO at 21st Bio\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/how-does-a-novel-food-get-to-your-plate/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/07/banner-website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240924T140000
DTEND;TZID=Europe/Brussels:20240924T153000
DTSTAMP:20260726T101527
CREATED:20240604T072713Z
LAST-MODIFIED:20240919T083820Z
UID:7902-1727186400-1727191800@www.europabio.org
SUMMARY:The Future of Biotech: The Role of Legislation within Investment for Innovation
DESCRIPTION:To celebrate the start of European Biotech Week 2024\, EuropaBio is organising a webinar to discuss the critical intersection of legislation and investment into innovation within the biotech industry. With clear political support for European leadership in biotech\, ensuring EU legislation become key enabler of investment for innovation will be essential to the EU’s global competitiveness and strategic open autonomy. \n\n\n\nThis webinar will bring together representatives from the biotech industry\, investor community\, and European institutions to explore the essential elements required to foster a thriving biotech and life sciences ecosystem in the EU. \n\n\n\nThe confirmed speakers and full agenda are: \n\n\n\nWelcome and introduction  \n\n\n\nMarica Nobile (Assobiotec Federchimica) \n\n\n\nKeynote speech: EU biotech & biomanufacturing initiative  \n\n\n\nHans Ingels (DG GROW) \n\n\n\nPanel: Impact of EU Legislation on Investment Opportunities  \n\n\n\nYordan Aleksandrov (Pfizer) \n\n\n\nSME – Anna Handschuh (Future Affairs) \n\n\n\nNicoló Giacomuzzi-Moore (CBEJU) \n\n\n\nKatrien Swerts (Kurma Partners) \n\n\n\nMarica Nobile (Assobiotec Federchimica) will moderate the panel and deliver closing remarks. \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/the-future-of-biotech-the-role-of-legislation-on-investment-for-innovation/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/06/GENERAL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230925T120000
DTEND;TZID=Europe/Brussels:20230925T131500
DTSTAMP:20260726T101527
CREATED:20230710T072650Z
LAST-MODIFIED:20230925T072852Z
UID:6450-1695643200-1695647700@www.europabio.org
SUMMARY:The economic power of biotechnology for Europe
DESCRIPTION:The world is at a key point of industrial and societal transition\, driven by advancing technology and the need for competitive\, resilient and sustainable economies. \n\n\n\nBiotechnology is at the heart of this transition across all sectors and it is playing a significant role in shaping Europe’s future. \n\n\n\nEuropean Biotech Week kick starts with a look at how biotechnology performs in the European Union’s economy. \n\n\n\nProfessor Dennis Ostwald\, founder and CEO of the WifOR Institute presents the 2023 edition of EuropaBio’s ‘Measuring the economic footprint of the biotechnology industry in Europe’. Professor Ostwald showcases how biotechnology contributes across healthcare and industrial sectors in the light of Europe’s response to Covid\, global supply chains stressed further by the Russian invasion of Ukraine\, and at a time when Europe also has ambitious climate change goals. \n\n\n\nSpeakers: \n\n\n\nProfessor Dr. Dennis A. Ostwald. Through his studies\, Prof. Ostwald aims to make the importance of health innovations visible and enable evidence-based decision making for a healthy society. He conducts research on topics such as health economics\, the value of impacts\, and international social policy. Prof. Ostwald studied Industrial Engineering and Management at the Technical University of Darmstadt\, Germany and received his PhD from the Chair of Finance and Economic Policy\, Prof. Dr. Dr. h.c. Bert Rürup\, on the topic “Growth and employment effects of the healthcare industry”. As Professor of Economic Research and International Management at the Steinbeis School of International Business and Entrepreneurship (SIBE)\, he wants to develop young talents into responsible managers who understand the interplay between social\, environmental and economic sustainability.  \n\n\n\n \n\n\n\nJoin EuropaBio to understand how biotechnology is increasing its role with Europe’s economy and discuss with Members what this means for sectors\, countries and citizens. \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/the-economic-power-of-biotechnology-for-europe/
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/07/GENERAL-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220929T140000
DTEND;TZID=Europe/Brussels:20220929T150000
DTSTAMP:20260726T101527
CREATED:20220830T122553Z
LAST-MODIFIED:20220922T103100Z
UID:5064-1664460000-1664463600@www.europabio.org
SUMMARY:European Biotech Week 2022: At the cutting edge of biotechnology for cardiovascular diseases: A World Heart Day special edition webinar
DESCRIPTION:Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients\, both in terms of innovative treatments\, but also via use of innovative prevention\, screening\, and testing measures. \n\n\n\nDuring this webinar\, which marks World Heart Day\, speakers will discuss how biomarker testing for genetically inherited risk factors for cardiovascular diseases is opening up new frontiers in healthcare\, and saving lives across the world. \n\n\n\nFeaturing speakers from the patient community\, research and academia\, and industry\, the conversation will also address the need to translate guidelines into practice\, and will end with an interactive Q&A. \n\n\n\nSpeakers: \n\n\n\nMarius Geanta\, Trustee and the Chair of the Policy Advisory Committee\, FH EuropeLena Lymperopoulou\, Global Policy Head Therapeutic Area Cardiovascular\, NovartisFlorian Kronenberg\, Full Professor and Head of the Institute of Genetic Epidemiology\, Medical University of InnsbruckJamie Wilkinson\, Healthcare Biotechnology Director\, EuropaBio\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-hc/
CATEGORIES:Biotech Week,EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-HC.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220927T140000
DTEND;TZID=Europe/Brussels:20220927T150000
DTSTAMP:20260726T101527
CREATED:20220830T105859Z
LAST-MODIFIED:20220914T134233Z
UID:5054-1664287200-1664290800@www.europabio.org
SUMMARY:European Biotech Week 2022: Innovative technologies in the EU green transition – spotlight on industrial biotechnology
DESCRIPTION:Industrial Biotechnology-derived products offer significant potential for contributing to overcoming many EU socio-economic and environmental challenges. It is not a new sector. On the contrary\, for thousands of years the power of microbes has been harnessed in food production and beverages. In the past century\, the applications for IB have expanded greatly with IB now providing living microorganisms and fermentation products that are used in sectors as diverse as food and feed\, agriculture\, detergents\, paper and pulp\, textiles\, fuels\, bioenergy\, and specialty chemicals. \n\n\n\nResearch and innovation are key drivers to accelerate the green transition. Indeed\, the EU Green Deal notes that “New technologies\, sustainable solutions and disruptive innovation are critical to achieve the objectives of the European Green Deal”. In this context\, a range of solutions will be needed. Alternatives to fossil-based products\, improved resource efficiency of industrial processes\, innovative food and feed are all targets where industrial biotechnology and bioeconomy innovation can deliver. \n\n\n\nThis webinar will discuss innovative solutions that can contribute towards the green transition\, with a focus on industrial biotechnology. It will zoom in on products of IB and their benefits and challenges\, also linking to the EU GMO regulatory framework and recent developments on new genomic techniques. \n\n\n\nSpeakers: \n\n\n\nMarc Leclerc\, Senior Regulatory Affairs Advisor\, NovozymesRachel Melnick\, Senior Scientific Program Manager\, Agriculture & Food Systems InstituteHans Genee\, Co-Founder and CSO\, Biosyntia\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-ib/
CATEGORIES:Biotech Week,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-IB.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220926T140000
DTEND;TZID=Europe/Brussels:20220926T151500
DTSTAMP:20260726T101527
CREATED:20220830T121819Z
LAST-MODIFIED:20220923T072206Z
UID:5060-1664200800-1664205300@www.europabio.org
SUMMARY:European Biotech Week 2022: Biotechnology for society\, sustainability and economies – transformative science for a changing world
DESCRIPTION:The 2022 European Biotech Week from EuropaBio opens with a look at how biotechnology is at the centre of Europe’s transformation to a healthy\, sustainable and competitive economy and society. \n\n\n\nJoin our Board Members from across Europe’s biotechnology spectrum to learn about biotech in action and its benefits in our every day lives\, as well as how it supports employment\, economic development and Europe’s place in the world. \n\n\n\nSpeakers: \n\n\n\nPatricia Malarkey\, Global Chief Innovation Officer\, DSMStefan Buchholz\, Senior VP R&D Nutrition and Care\, EvonikTom Bols\, Head of Government Affairs and Patient Advocacy\, PTC TherapeuticsAnnemeik Verkamman\, Managing Director\, HollandBio\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-biotechnology-for-society-sustainability-and-economies-transformative-science-for-a-changing-world/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Events-Template-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210930T140000
DTEND;TZID=Europe/Brussels:20210930T150000
DTSTAMP:20260726T101527
CREATED:20210614T154210Z
LAST-MODIFIED:20211001T075124Z
UID:2727-1633010400-1633014000@www.europabio.org
SUMMARY:The small companies changing the world: Meet the science and business of sustainability
DESCRIPTION:With the Green Deal\, the EU has set an ambitious strategy towards climate neutrality\, transitioning to a circular economy and a more sustainable food system. Many aspects of our lives must change to achieve these ambitions: a reduction in only high profile targets\, such as transport\, will not be enough. Our food\, cosmetics\, clothes\, and other products and consumables across our lives need to get leaner and greener and biotechnology solutions can contribute towards responding to this need. \n\n\n\nConfirmed speakers: \n\n\n\nJuan Medina\, Co-Founder and CEO Kaffe BuenoTaichi Ochi\, Senior Business Developer\, EV BiotechCyrille Pauthenier\, CEO Abolis\n\n\n\nJoin us to find out how small companies across Europe are rising to the challenge to innovate for our sustainable futures. \n\n\n\n\nSlides\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/the-small-companies-changing-the-world-meet-the-science-and-business-of-sustainability/
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/European-Biotech-Week-Event-Banner-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210929T120000
DTEND;TZID=Europe/Brussels:20210929T133000
DTSTAMP:20260726T101527
CREATED:20210614T150425Z
LAST-MODIFIED:20210929T123032Z
UID:2723-1632916800-1632922200@www.europabio.org
SUMMARY:Investing in healthcare - How can the revision of the general pharmaceutical legislation better attract investors in the future?
DESCRIPTION:The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof\, patient-oriented and leading life science and biotechnology sector in the EU. \n\n\n\nThe first aim of this initiative should be to regain EU’s global leadership as a home for R&D and cutting-edge industry to secure high-quality care for citizens at affordable levels. \n\n\n\nNew biotechnology-derived vaccines and treatments have helped to tackle numerous life-threatening illnesses. Targeted treatments\, like cell and gene therapies\, and new mRNA platforms are paving the way for future treatments. COVID-19 has shown that only science-based and high-risk research embedded in a strong life science industry ecosystem can bring the lasting solutions to health challenges. \n\n\n\nEmerging biopharmaceutical companies account for over 70% of the research pipeline contributing to a vibrant sector. The EU biotech sector\, mostly made up of SMEs\, relies on robust IP and targeted incentives that enable companies to raise risk capital\, with the prospect of remaining unprofitable for years. It is due to these set of incentives that the EU has retained its capability to produce breakthrough innovation. To keep pace with the rest of the world\, future incentives should reflect the economic challenges of developing health innovation. \n\n\n\nJoin us to find out how investing in R&D for innovative medicines and treatments is essential to support a competitive European biotechnology industry. \n\n\n\nConfirmed speakers:: \n\n\n\n\nJuozas OLEKAS\, Member of the European Parliament\, S&D\, Lithuania \n\n\n\nStefan Gijssels\, SEBOIO Health Policy Consulting and Co-founder of digestive Cancer Europe \n\n\n\nIngrid Maes\, Co-founder of Inovigate\, 25 years of experience in Life Sciences Expertise in New Product Development and Market Introduction \n\n\n\nIsabelle Schubert\, Global Head IP Strategy at Novartis \n\n\n\nOskar Slotboom\, General Partner at BGV (BioGeneration Ventures) \n\n\n\n\nSlides\n\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/investing-in-healthcare-how-can-the-revision-of-the-general-pharmaceutical-legislation-better-attract-investors-in-the-future/
LOCATION:Invest Europe
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/European-Biotech-Week-Event-Banner-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210927T153000
DTEND;TZID=Europe/Brussels:20210927T170000
DTSTAMP:20260726T101527
CREATED:20210614T145612Z
LAST-MODIFIED:20210922T105308Z
UID:2714-1632756600-1632762000@www.europabio.org
SUMMARY:Biotechnology for society - Turning science into a sustainable and healthy world
DESCRIPTION:EuropaBio’s launch meeting for Biotech Week will share how science finds its way to an end use\, whether it is a new medicine\, or a product developed using new scientific processes.  \n\n\n\nEurope sets the global standard for consumer and environmental protection.  This translates into a regulatory framework for different sectors through which novel products must pass before they can be used in Europe.  The European Medicines Agency (EMA) and the European Food Safety Authority (EFSA) are the gateway for new products and play a critical role in how Europe innovates safely. \n\n\n\nIt can be complicated\, particularly for new science. So how does Europe deliver innovation to benefit patients and our planet whilst ensuring the high standards and safety that we expect? \n\n\n\nThe Covid response from regulators demonstrated how Europe can be agile and rapid for the vaccines that are now helping Europe restore a safe and open society.  Our launch event for Biotech Week brings together the community that develops products from science to consumers\, highlighting how we can evolve our regulatory systems help develop safe societies and a competitive Europe. \n\n\n\nConfirmed speakers: \n\n\n\nAna Maria Bravo\, Director of Government Affairs\, IFFWolfgang Gelbmann\, Senior Scientific Officer\, Nutrition Unit\, EFSADamian Gilkerson\, CSL Behring Executive Director Therapeutic Area EU\, Commercial Operations EuropeEmmanuelle Voisin\, CEO Voisin Consulting Life Sciences\n\n\n\nJoin us to find out how science reaches its target and help EuropaBio kick start a week dedicated to the explanation and celebration of biotechnology. \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/biotechnology-for-society-turning-science-into-a-sustainable-and-healthy-world/
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/European-Biotech-Week-Event-Banner-2.png
END:VEVENT
END:VCALENDAR